← 產業報告目錄
Gastroesophageal Reflux Disease Therapeutics Market Size, Share & Trends Analysis Report By Drug Type (Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), and Pro-Kinetic Agents), By Region, And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-19頁數 180報告編號 INSIGHTACE-8fe5819217
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
In 2021, the Gastroesophageal Reflux Disease Therapeutics Market worldwide was assessed at USD 4.9 Bn. Analysts project it will expand to USD 5.9 Bn by 2034, at a CAGR of 1.9% spanning 2025 to 2034.
Gastroesophageal Reflux Disease Therapeutics encompasses key industry insights & findings from the report:
The demand for gastroesophageal reflux disease therapeutics is expected to rise due to the surging number of initiatives by the government and n. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the surging emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, driven by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gastroesophageal Reflux Disease Therapeutics Market Snapshot
Chapter 4. Global Gastroesophageal Reflux Disease Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Drug Type Estimates & Trend Analysis
5.1. by Drug Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Drug Type:
5.2.1. Antacids
5.2.2. H2 Receptor Blockers
5.2.3. Proton Pump Inhibitors (PPIs)
5.2.4. Pro-kinetic agents
Chapter 6. Gastroesophageal Reflux Disease Therapeutics Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
6.1.2. North America Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
6.2. Europe
6.2.1. Europe Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
6.2.2. Europe Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
6.3. Asia Pacific
6.3.1. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
6.3.2. Asia Pacific Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
6.4. Latin America
6.4.1. Latin America Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
6.4.2. Latin America Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
6.5. Middle East & Africa
6.5.1. Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
6.5.2. Middle East & Africa Gastroesophageal Reflux Disease Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. AstraZeneca;
7.2.2. Aurobindo Pharma Limited
7.2.3. Cadila Pharmaceuticals Limited
7.2.4. Camber Pharmaceuticals Inc.
7.2.5. CHEPLAPHARM Arzneimittel GmbH
7.2.6. Daewoong Pharmaceutical Co., Ltd
7.2.7. Eisai Co. Ltd.
7.2.8. EndoStim, Inc.
7.2.9. GlaxoSmithKline PLC
7.2.10. Ironwood Pharmaceuticals, Inc.;
7.2.11. Jeil Pharmaceutical Co., Ltd.
7.2.12. Johnson & Johnson Services, Inc.
7.2.13. Novartis AG
7.2.14. Phathom Pharmaceuticals Inc.
7.2.15. Reckitt Benckiser Group PLC
7.2.16. Sebela Pharmaceuticals
7.2.17. SFJ Pharmaceuticals Group
7.2.18. SRS Life Sciences Pte. Ltd.
7.2.19. Sun Pharmaceutical Industries Limited
7.2.20. Takeda Pharmaceutical Company Limited.
7.2.21. Teva Pharmaceuticals Industries Limited
7.2.22. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們